Shree Ganesh Remedies Intrinsic Value
SGRL • Healthcare
Current Stock Price
₹420.05
Primary Intrinsic Value
₹339.68
Market Cap
₹546.1 Cr
-46.9%
Downside
Median Value
₹223.08
Value Range
₹126 - ₹340
Assessment
Trading Above Calculated Value
Safety Margin
-88.3%
SGRL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹339.68 | ₹271.74 - ₹407.62 | -19.1% | EPS: ₹15.44, Sector P/E: 22x |
| Book Value Method | asset | ₹223.08 | ₹200.77 - ₹245.39 | -46.9% | Book Value/Share: ₹111.54, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹190.77 | ₹171.69 - ₹209.85 | -54.6% | Revenue/Share: ₹95.38, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹307.69 | ₹276.92 - ₹338.46 | -26.7% | EBITDA: ₹40.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹323.91 | ₹259.13 - ₹388.69 | -22.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹126.02 | ₹113.42 - ₹138.62 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹238.55 | ₹214.70 - ₹262.41 | -43.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹210.03 | ₹189.03 - ₹231.03 | -50.0% | ROE: 13.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹196.85 | ₹177.16 - ₹216.54 | -53.1% | EPS: ₹15.44, BVPS: ₹111.54 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SGRL Intrinsic Value Analysis
What is the intrinsic value of SGRL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Shree Ganesh Remedies (SGRL) is ₹223.08 (median value). With the current market price of ₹420.05, this represents a -46.9% variance from our estimated fair value.
The valuation range spans from ₹126.02 to ₹339.68, indicating ₹126.02 - ₹339.68.
Is SGRL undervalued or overvalued?
Based on our multi-method analysis, Shree Ganesh Remedies (SGRL) appears to be trading above calculated value by approximately 46.9%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.52 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 32.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.65x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Shree Ganesh Remedies
Additional stock information and data for SGRL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹31 Cr | ₹13 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹31 Cr | ₹15 Cr | Positive Free Cash Flow | 7/10 |
| March 2020 | ₹5 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2019 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |